NCT05724576View on ClinicalTrials.gov

Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Safety Issues
Interventions
BIOLOGICAL

OmniMSC-AMI

10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).

Trial Locations (1)

Unknown

RECRUITING

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

Taiwan Bio Therapeutics Inc.

INDUSTRY